First obesity management service to be launched in NI

Northern Ireland’s first regional obesity management service has been approved by the health minister.

Mike Nesbitt’s announcement follows a public consultation by the Department of Health (DOH) on the proposed introduction of such a service.

Currently, health service patients in Northern Ireland do not have access to specialist weight management provision, including “innovative weight loss injections/medications,” the DoH said.

The first phase, which is scheduled to begin in 2026, will focus on the development of a community-based service where patients will have access to lifestyle support as well as obesity medication, if clinically appropriate.

The department said: “The service will support access to weight loss medication in line with National Institute for Health and Care Excellence guidance.

“Any rollout will be carefully managed in a phased manner to ensure that treatment is provided in a safe and effective manner.”

They added that further phases of the service will develop, but they would be subject to funding and could include “other interventions such as bariatric (weight loss) surgery”.

Nesbitt said the service is a “significant step forward”.

“Establishing a Regional Obesity Management Service will also bring us into line with other parts of the UK”.

He said the service will be “a phased introduction and will take time and sustained investment to be fully established”.

“A very important day for public health”, he concluded.

There are two drugs on the market – semaglutide, marketed under the brand name Wegovy, and tirzepatide, sold as Mounjaro. Semaglutide is also used in the type 2 diabetes treatment Ozempic.

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, thigh or stomach.

They work as an appetite suppressant by mimicking a hormone called glucagon-like peptide-1 (GLP-1).

This is an intestinal hormone which is released after eating, and typically makes people feel fuller.

Mounjaro also affects another hormone, glucose-dependent insulinotropic polypeptide (GIP), which affects metabolism and helps regulate energy balance.

Patients generally start on a low dose which is gradually increased until they reach a higher maintenance dose.

Read more here.